TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12091327
Drug: Lamivudine prophylaxis
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine prophylaxis administered to 13 patients for 1 to 60 days (mean, 15 days) before immunosuppressive treatment and continued for 0.5 to 24 months (mean, 7 months) after initiation of immunosuppression.
Study: 10337288
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide gel used nightly for 2 weeks
Study: 9005783
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Ofloxacin
Study: 2003657
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg labetalol
Study: 2003657
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg labetalol
Study: 30328648
Drug: Zolpidem (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (0.25 mg/kg)
Study: 25704750
Drug: ASP015K (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP015K (10, 25, 60, 100 mg twice daily; 50 mg once daily)
Study: 20650784
Drug: Tested preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tested preparation (orally disintegrating tablets of pentoxyverine citrate)
Study: 20650784
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (orally disintegrating tablets of pentoxyverine citrate)
Study: 12762636
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 3 capsules (570 mg of iodine)
Study: 12762636
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 1 ml of Lipiodol UF (480 mg of iodine)
Study: 12762636
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of Lipiodol
Study: 12762636
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Lipiodol
Study: 10391813
Drug: Intradermal BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal BCG vaccination
Study: 6128313
Drug: Medazepam 10
Normalized name: medazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medazepam 10 mg
Study: 27027671
Drug: Palliation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliation of symptoms with oxygen and morphine
Study: 27027671
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to wishes
Study: 18500678
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg pioglitazone over nine days
Study: 15598942
Drug: UFT 400
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 400 mg/m² for 1 year after surgery
Study: 9475816
Drug: Regular team
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular team interventions involving a pharmacist, physician, nurses, undernurses, and nurse's aides discussing drug therapy.
Study: 8584609
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg NNC 01-0687
Study: 8584609
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg NNC 01-0687 administered t.i.d. for 14 days
Study: 2223339
Drug: lignocaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine 1.5 mg kg‐1 i.v. 1 min before laryngoscopy
Study: 2223339
Drug: lignocaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine 1.5 mg kg‐1 i.v. 2 min before laryngoscopy
Study: 2223339
Drug: lignocaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine 1.5 mg kg‐1 i.v. 3 min before laryngoscopy
Study: 372525
Drug: Aspirin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3.6 gm/day)
Study: 24088361
Drug: SR-IFN-α (9,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR-IFN-α (9, 18, 27, and 36 MIU subcutaneous doses)
Study: 21850272
Drug: Intranasal GHRH
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal GHRH (600 µg)
Study: 11157327
Drug: 1046 kJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1046 kJ energy load supplement
Study: 11157327
Drug: 2092 kJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2092 kJ energy load supplement
Study: 11157327
Drug: Fat-rich supplement
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-rich supplement (1046 kJ)
Study: 11157327
Drug: Carbohydrate-rich supplement
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich supplement (1046 kJ)
Study: 8092581
Drug: Cryoanesthesia using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoanesthesia using freon spray for venepuncture
Study: 2663609
Drug: Glucagon and
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon and insulin infusion (1 mg glucagon and 10 units insulin twice daily for one week)
Study: 22216499
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg theophylline orally
Study: 23661283
Drug: Trazodone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (25 mg)
Study: 21740564
Drug: Neutral writing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral writing condition (writing about facts regarding heart disease and its treatment)
Study: 7634784
Drug: Potent topical
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent topical corticosteroid (betamethasone‐17‐valerate) applied 2x daily for 7 days
Study: 7634784
Drug: Vehicle applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle applied 2x daily for 7 days
Study: 6539997
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cyclophosphamide 1 Gm/M2 each month for six months; cis-platinum 100 mg/M2 each month for four months; combination chemotherapy (CISCA) for one patient)
Study: 18564001
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg/dose every 8 hours for 15 days)
Study: 7032273
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms trivalent chromium in 5 ml water (Cr)
Study: 7032273
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml plain water (W)
Study: 24196948
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) with valproic acid
Study: 19772514
Drug: Regular nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular nebulized glucocorticoid (400 microg beclomethasone bid) plus prn bronchodilator (2500 microg salbutamol)
Study: 19772514
Drug: prn nebulized
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: prn nebulized bronchodilator/glucocorticoid combination (800 microg beclomethasone/1600 microg salbutamol)
Study: 10052021
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of vitamin C (C)
Study: 7734260
Drug: Neostigmine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.04 mg kg‐1
Study: 7734260
Drug: Pyridostigmine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 0.3 mg kg‐1
Study: 7734260
Drug: Edrophonium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.25 mg kg‐1 with Pyridostigmine 0.15 mg kg‐1
Study: 6174864
Drug: Higher-dose Human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose Human leukocyte interferon
Study: 27419258
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined oral contraceptives (COCs)
Study: 24464122
Drug: Vibration anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration anesthesia with dermal filler injections
Study: 24464122
Drug: Dermal filler
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal filler injections alone (Control)
Study: 17589893
Drug: Octreotide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (0.5 mg s.c. every 8 h for 6 weeks, followed by octreotide LAR 20 mg i.m. at week 4-8, and octreotide LAR 30 mg i.m. every 4 weeks thereafter)
Study: 16243985
Drug: IA with
Normalized name: nutritional therapy for tyrosinemia with iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA with bupivacaine (0.25%) and clonidine (1 microg/kg) and morphine (5 mg)
Study: 9657539
Drug: Fosinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (20 mg o.d.)
Study: 8075734
Drug: Vaccine information
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine information pamphlets
Study: 2673323
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo spray with vacuum cleaning
Study: 2673323
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo spray without vacuum cleaning
Study: 4619836
Drug: Diazepam in
Normalized name: diazePAM Intensol
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam in addition to standard treatment
Study: 25138736
Drug: H. persicum
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. persicum hydroalcoholic fruit extract (300 mg/day)
Study: 21719012
Drug: Low-dose epidural
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose epidural analgesia (LEA)
Study: 16847150
Drug: Early intensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intensive simvastatin therapy
Study: 12878372
Drug: Eprosartan (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (600 mg/d for 1 week)
Study: 9499493
Drug: Conventional pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pretreatment (heparin 15,000 I.E. and aspirin 500 mg i.v.)
Study: 9710890
Drug: Interleukin-1 receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Interleukin-1 receptor antagonist (IL-1ra)
Study: 31491796
Drug: Aminocaproic acid
Normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminocaproic acid (2,000 mg per dose, three doses: 2 hours before surgery, 6 and 12 hours after surgery)
Study: 31491796
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1,300 mg per dose, three doses: 2 hours before surgery, 6 and 12 hours after surgery)
Study: 31585740
Drug: Oleuropein-enriched chocolate
Normalized name: oleuropein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleuropein-enriched chocolate (40 g)
Study: 31585740
Drug: Control chocolate
Normalized name: CHOCOLATE
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control chocolate spread (40 g)
Study: 28455172
Drug: One IPV
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One IPV dose at 14 weeks (SP‐1, GSK‐1, BBio‐1)
Study: 28455172
Drug: Two IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two IPV doses at 14 and 36 weeks (SP‐2, GSK‐2, BBio‐2)
Study: 28455172
Drug: One IPV
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One IPV dose
Study: 28455172
Drug: Two IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two IPV doses
Study: 23183529
Drug: BOC/RGT (boceprevir
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOC/RGT (boceprevir plus peginterferon-ribavirin using response guided therapy)
Study: 21803011
Drug: Dronabinol 2.5
Normalized name: dronabinol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol 2.5 mg
Study: 21803011
Drug: Dronabinol 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol 5.0 mg
Study: 19398460
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus administration of meropenem (1 g 8 hourly)
Study: 19398460
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of meropenem (1 g)
Study: 19398460
Drug: All dosing
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosing regimens (intermittent bolus, extended, continuous infusion)
Study: 19398460
Drug: Extended or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended or continuous infusion of meropenem
Study: 15496218
Drug: Donepezil HCl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil HCl 5 mg (oral) once daily from days 6 to 29
Study: 11669506
Drug: Conventional AChE
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional AChE inhibitors (rivastigmine and donepezil)
Study: 3543239
Drug: Cyclophosphamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (500 mg/m2 day 1), imidazole carboxamide (250 mg/m2 days 1 through 5), and doxorubicin (50 mg/m2 day 1)
Study: 3543239
Drug: Cyclophosphamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2)
Study: 27619827
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg long‐acting octreotide once every 4 weeks for 52 weeks, in addition to standard care
Study: 27619827
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg long‐acting octreotide
Study: 18756741
Drug: Therapy leading
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy leading to a decrease in NT-pro BNP levels
Study: 18756741
Drug: Therapy leading
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy leading to a decrease in TNF-alpha levels
Study: 18756741
Drug: Therapy leading
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy leading to a decrease in IL-6 levels
Study: 10796063
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg enteric-coated aspirin
Study: 1404679
Drug: Regular aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular aspirin
Study: 8729092
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of n-3 polyunsaturated fatty acids (PUFA) from fish oils
Study: 3956107
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose AVP (0.0125 m‐unit min‐1 kg‐1)
Study: 3956107
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose AVP (0.3 m‐unit min‐1 kg‐1)
Study: 30171161
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg [14C]finerenone (single oral administration)
Study: 24248184
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg (1000 IU) vitamin D3
Study: 24248184
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg (400 IU) vitamin D3
Study: 21090563
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg/kg every 3 weeks for four doses)
Study: 21090563
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral budesonide (9 mg/d with gradual taper through week 16)
Study: 16291162
Drug: Alimemazine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alimemazine (0.25 mg/kg 3 times a day, maximum 2.5 mg per dose)
Study: 10224206
Drug: d4T monotherapy
Normalized name: STAVUDINE (d4T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d4T monotherapy (arm 1)
Study: 8722345
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (CY) administered as a 2-h infusion (60 mg/kg) for 2 days with MESNA as intermittent bolus infusion (20% of CY dose) every 6 h
Study: 8722345
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (CY) administered by continuous infusion (1500 mg/m2/day) for 4 days with MESNA administered concomitantly at an equivalent dose to CY by continuous infusion
Study: 1853147
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA) at a dose of 15 mg/kg/day
Study: 1853147
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at a dose of 15 mg/kg/day
Study: 1853147
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CDCA and UDCA (7.5 + 7.5 mg/kg/day)
Study: 6430666
Drug: 2.6 mg
Normalized name: menthol 2.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6 mg nitroglycerin
Study: 6430666
Drug: 6.5 mg
Normalized name: menthol 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg nitroglycerin
Study: 6430666
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nitroglycerin
Study: 6430666
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nitroglycerin
Study: 6430666
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nitroglycerin (6 hours later)
Study: 28918212
Drug: Miglitol (α-glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (α-glucosidase inhibitor)
Study: 22093142
Drug: Intensive multifactorial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multifactorial treatment (IT) including lifestyle advice and strict regulation of metabolic parameters
Study: 15656848
Drug: Relaxation breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation breathing exercise combined with physical exercise for 30 minutes daily for six weeks
Study: 10456815
Drug: Ketamine (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (50, 100, and 200 ng x mL(‐1))
Study: 10456815
Drug: Alfentanil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (50 ng x mL(‐1))
Study: 858795
Drug: Audiovisual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audiovisual treatment depicting a dyadic psychotherapy situation with varying therapist age and status.
Study: 28718236
Drug: Metformin Immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin Immediate Release (MIR) 1000 mg twice daily
Study: 28718236
Drug: Metformin Extended
Normalized name: metFORMIN Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin Extended Release (MXR) 1000 mg twice daily
Study: 28718236
Drug: Metformin Extended
Normalized name: metFORMIN Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin Extended Release (MXR) 500 mg twice daily
Study: 25371036
Drug: Fixed bladder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed bladder volume of 500 ml
Study: 23573880
Drug: Bidirectional knotless
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bidirectional knotless barbed suture (0-Quill™; Angiotech Pharmaceuticals, Inc.)
Study: 18215977
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) therapy
Study: 10892659
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/day for 3 days)
Study: 8814373
Drug: Granisetron (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (single intravenous dose)
Study: 8814373
Drug: Ondansetron (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (twice-daily oral for 3 or 4 days)
Study: 24681179
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg parecoxib injection 30‐45 min before anesthesia induction and 4 ml saline injection when gallbladder was removed
Study: 24681179
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml saline injection 30‐45 min before anesthesia induction and 40 mg parecoxib injection when gallbladder was removed
Study: 24681179
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml saline injection 30‐45 min before anesthesia induction and the time when gallbladder was removed
Study: 22063735
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment within the first week after onset of symptoms
Study: 17636090
Drug: Ecopipam 100
Normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam 100 mg daily for 12 weeks
Study: 17636090
Drug: Ecopipam 100
Normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam 100 mg daily for 52 weeks
Study: 15691239
Drug: Inhaled hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled hypertonic saline (4.5% for ≤ 15 min without bronchodilator pretreatment)
Study: 15691239
Drug: Inhaled methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methacholine (maximum cumulative dose 4 micromol)
Study: 10037073
Drug: G-CSF (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (100 to 250 microg) given daily until neutrophil counts rose to greater than 1000/microL
Study: 10037073
Drug: Untreated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated group receiving antibiotic therapy only
Study: 2033693
Drug: External sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: External sequential pneumatic compression stockings
Study: 2033693
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus dihydroergotamine
Study: 6763394
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose tobramycin